Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Benjamin Scharfstein

Surgery Bristol, TN Medical Doctor

NPI 1497850515 CMS profile 339683

1 Medical Park Blvd Ste 250W, Bristol, TN 37620

Open in the dashboard

General payments

$29,749

155 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Scharfstein of Bristol, TN is reported in the CMS Open Payments database as having received $29,749 across 155 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,998 26
2024 General $3,615 43
2023 General $356 10
2022 General $17,230 28
2021 General $291 8
2020 General $3,064 5
2019 General $3,194 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Scharfstein
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Benjamin Scharfstein were reported at $1,998. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Benjamin Scharfstein Surgery median Middle half National median
2019 $3,194 $253 $82–$1,521 $163
2020 $3,064 $131 $40–$706 $114
2021 $291 $168 $50–$904 $132
2022 $17,230 $224 $76–$1,218 $149
2023 $356 $253 $82–$1,255 $160
2024 $3,615 $279 $90–$1,381 $164
2025 $1,998 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $28,392 96 payments
  2. W. L. Gore & Associates, Inc. $204 4 payments
  3. CONMED Corporation $174 3 payments
  4. Medtronic, Inc. $96 5 payments
  5. LeMaitre Vascular, Inc. $88 4 payments
  6. Portola Pharmaceuticals, Inc. $78 4 payments
  7. Alexion Pharmaceuticals, Inc. $57 4 payments
  8. Integra LifeSciences Corporation $50 2 payments
  9. Medtronic Vascular, Inc. $48 3 payments
  10. Leica Microsystems Inc. $43 2 payments
  11. Other $518 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $19,091 8 payments
  2. Travel and Lodging $5,653 18 payments
  3. Food and Beverage $4,991 128 payments
  4. Gift $14 1 payment
Products named General payments · program years 2019–2025
  1. DAVINCI XI $15,036 6 payments
  2. Da Vinci Surgical System $13,356 90 payments
  3. GORE SYNECOR Biomaterial $187 3 payments
  4. AIRSEAL $174 3 payments
  5. ANDEXXA Hematology/Neurology $78 4 payments
  6. ANDEXXA Rare Disease $72 5 payments
  7. Integra Recon-Skin And Wound $50 2 payments
  8. Integra Recon-Skin And Wound $50 2 payments
  9. PRIMATRIX $50 2 payments
  10. Integra Recon-Skin And Wound $50 2 payments
  11. Other $804 43 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

86

Median for General Surgery: 59

Drug cost

$1,911

Median for General Surgery: $393

Branded share of claims

58.1%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 22 $1,315
Erythromycin Erythromycin Base Brand 11 $368
Ondansetron Odt Ondansetron Brand 17 $108
Neomycin Sulfate Generic 12 $62
Oxycodone Hcl Generic 12 $40
Pantoprazole Sodium Generic 12 $19

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 104 billing codes

Paid by Medicare

$97,175

Medicare's payments for the services billed

Medicare patients

290

Average age 74

Services billed

626

152 women, 138 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 42%
Ischemic heart disease 37%
Chronic kidney disease 33%
Depression 31%
Cancer 25%
COPD 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

155 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record